A Phase 2 Study Evaluating the Safety and Efficacy of JS207 With or Without JS015 in Combination With Chemotherapy in Patients With Colorectal Cancer

NCT06885385 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Advanced Colorectal Cancer

Interventions

BIOLOGICAL: JS207
BIOLOGICAL: JS015
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Shanghai Junshi Bioscience Co., Ltd.